OakChart

Atrium Therapeutics Inc

RNAHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

7.96-0.27 (-3.28%)
2026-11-11 22:43 CET
Market cap
183.33 USD m
Revenue, TTM
3.00 USD m
Net income, TTM
-20.19 USD m
Free cash flow, TTM
-3.96 USD m
EPS diluted, TTM
-1.18
P/E
-
Compare

Price

RNA against its 20 and 50-day averages
2050beat
8.0010.0012.0014.00861K1.7MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26RNAclose 7.9620-day 8.2050-day 8.927.9652w low

52.5% under the 52-week high of 16.77 on 5 Mar 2026. 52-week low 7.49 on 19 Oct 2026. Last 15 sessions, 15.6% high to low

Volume 0.46× normal · the line is the 50-bar volume average

Profile

RNA
52-week range, 5% of the way up
7.4916.77

Atrium Therapeutics, Inc. operates as a biopharmaceutical company that provides RNA therapeutics services to the heart to transform the standard of care for people living with cardiomyopathies. Its products pipeline includes two lead development candidates: ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, both conditions are severe, life-threatening, rare autosomal dominant progressive cardiomyopathies with no approved treatment options and high unmet need. The company was founded on September 30, 2025 and is headquartered in San Diego, CA.

IPOJun 12, 2020
ATR, 14d0.38
Rel volume0.46
Short float17.34%
Insider own2.96%
Inst own64.10%

Snapshot

6 groups

Valuation

Index-
Market Cap177.32M
Enterprise Value-85.21M
Income-
Sales-
Book/sh12.54
Cash/sh11.86
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOJun 12, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.63
P/C0.67
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio8.73
Current Ratio8.73
Debt/Eq0.01
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-
EPS next Y-6.45
EPS next Q-0.81
EPS this Y4.12%
EPS next Y-50.16%
EPS next 5Y-11.31%
EPS past 3/5Y-178.43% -
Sales past 3/5Y38.09% -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-170.95%
Sales Q/Q90.97%
EarningsAug 13 AMC
EPS/Sales Surpr.16.75% 350.58%

Ownership

Insider Own2.96%
Insider Trans0.00%
Inst Own64.10%
Inst Trans-5.44%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-2.88%
SMA50-10.79%
SMA200-33.17%
Trades-

Technical

Shs Outstand22.28M
Shs Float21.62M
Short Float17.34%
Short Ratio13.17
Short Interest3.75M
52W High16.77 -52.53%
52W Low7.49 6.28%
Volatility4.18% 4.63%
ATR (14)0.38
RSI (14)39.16
Beta-
Rel Volume0.46
Avg Volume284.61K
Volume130,133

Performance

Perf Week-8.29%
Perf Month2.71%
Perf Quarter-35.44%
Perf Half Y-40.15%
Perf YTD-45.40%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price22.00
Prev Close8.23
Price7.96
Change %-3.28%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 22, 2026InitiatedRRoth CapitalBuy$15+88.4%
Aug 06, 2026InitiatedHH.C. WainwrightBuy$25+214.1%
Jun 18, 2026InitiatedCCantor FitzgeraldOverweight$25+214.1%
May 15, 2026InitiatedLLeerink PartnersOutperform$25+214.1%
Mar 11, 2026InitiatedWWells FargoOverweight$25+214.1%
Sep 17, 2025InitiatedRRoth CapitalBuy$62+678.9%
Jul 10, 2025ResumedGGoldmanBuy$55+591.0%
Jun 24, 2025InitiatedBBernsteinOutperform$50+528.1%
Jun 17, 2025InitiatedWWolfe ResearchOutperform$55+591.0%
Jun 11, 2025InitiatedRRaymond JamesStrong Buy$65+716.6%

Peers

Mkt cap
TickerCompanyMkt cap
TNYATenaya Therapeutics Inc84.61M
LXEOLexeo Therapeutics Inc252.01M
RCKTRocket Pharmaceuticals Inc272.24M
DYNDyne Therapeutics Inc3.37B
ADRXADARx Pharmaceuticals Inc1.47B
KARDKardigan Inc1.47B
SLNSilence Therapeutics Plc ADR1.23B
ARWRArrowhead Pharmaceuticals Inc6.97B
EWTXEdgewise Therapeutics Inc5.21B
CYTKCytokinetics Inc8.15B

Insider trading

13 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Hughes Steven GeorgeChief Medical OfficerJan 21 '26Sale72.454,895354,64331,599Jan 23 05:34 PM
Boyce SarahPresident and CEOJan 21 '26Sale72.4514,3871,042,338269,007Jan 23 05:34 PM
Flanagan W. MichaelChief Scientific OfficerJan 21 '26Sale72.456,534473,38885,093Jan 23 05:33 PM
MacLean Michael FChief Financial OfficerJan 21 '26Sale72.454,542329,06859,290Jan 23 05:33 PM
LEVIN ARTHUR ADirectorJan 21 '26Sale72.451,758127,36716,562Jan 23 05:33 PM
McCarthy TeresaChief Human Resources OfficerJan 21 '26Sale72.452,929212,206113,938Jan 23 05:33 PM
Boyce SarahPresident and CEOJan 07 '26Sale72.238,576619,444283,394Jan 09 05:13 PM
Calderaro Charles IIIChief Technical OfficerJan 07 '26Sale72.233,727269,20149,797Jan 09 05:13 PM
McCarthy TeresaChief Human Resources OfficerJan 07 '26Sale72.231,965141,932116,867Jan 09 05:13 PM
Moriarty John BChief Legal OfficerJan 07 '26Sale72.232,374171,47474,557Jan 09 05:12 PM
MacLean Michael FChief Financial OfficerJan 07 '26Sale72.231,974142,58263,832Jan 09 05:12 PM
Hughes Steven GeorgeChief Medical OfficerJan 07 '26Sale72.232,373171,40236,494Jan 09 05:12 PM
Flanagan W. MichaelChief Scientific OfficerJan 07 '26Sale72.232,373171,40291,627Jan 09 05:12 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M

News

latest 14 of 200
  • Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026 (PR Newswire)
  • Atrium Therapeutics Doses First Patient in Corventis, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome (PR Newswire)
  • Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
  • Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing (PR Newswire)
  • Atrium Therapeutics Announces $50 Million Private Placement (PR Newswire)
  • Atrium Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire)
  • Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
  • Atrium Therapeutics Reports Second Quarter 2026 Financial Results (PR Newswire)
  • Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration (PR Newswire)
  • Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls (The Fly)
  • Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
  • Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
  • Atrium Therapeutics Reports First Quarter 2026 Financial Results (PR Newswire)
  • Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-1.180-1.418-1.1803.000.674
2026Q12026-05-14-0.970-1.050-0.97219.642.001
2025Q42026-02-25-0.610--1.7022.10--
2025Q32025-11-10-0.127-0.109-0.12712.501.9414
2025Q22025-08-07-0.121-0.096-0.7533.851.4915
2025Q12025-05-08-0.090-0.088-0.4361.602.3712
2024Q42025-02-27-0.080-0.079-0.6732.971.6310
2024Q32024-11-07-0.065-0.071-0.0652.344.0710
2024Q22024-08-09-0.065-0.076-0.0662.052.638
2024Q12024-05-09-0.079-0.080-0.0793.502.577
2023Q42024-02-28-0.079-0.066-0.0802.1912.216
2023Q32023-11-08-0.071-0.076-0.0712.822.216
2023Q22023-08-08-0.066-0.079-0.0662.322.148
2023Q12023-05-09-0.074-0.084-0.0742.212.048
2022Q42023-02-28-0.088-0.089-0.0882.772.168
2022Q32022-11-08-0.082-0.093-0.0822.482.138

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-0.205-0.180-0.2056.795.48
2021FY-0.285-0.273-2.8499.339.51
2022FY-0.334-0.336-3.3369.228.32
2023FY-0.291-0.265-0.3739.5619.58
2024FY-0.289-0.287-1.46810.909.74
2025FY-4.097--4.48015.60-
2026FY--4.296--35.02
2027FY--6.450--2.67
2028FY--6.178--4.00
2029FY--4.590--0.00
2030FY--4.430--0.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-2840015.0015.0015.00
2026Q3S2026-10-2143015.0015.0015.00
2026Q3S2026-08-1433015.0015.0015.00
2026Q3S2026-08-133000.670.002.00
2026Q3S2026-06-173000.670.002.00
2026Q3S2026-05-152001.000.002.00
2026Q3S2026-03-101002.002.002.00
2026Q3R2026-10-28200-0.55-0.60-0.49
2026Q3R2026-08-14220-0.55-0.60-0.49
2026Q3R2026-08-13200-1.43-1.43-1.42
2026Q3R2026-07-29200-1.43-1.43-1.42
2026Q3R2026-05-15201-1.43-1.43-1.42
2026Q3R2026-03-10100-1.04-1.04-1.04
2026Q3E2026-10-28500-0.81-1.70-0.49

Estimate history

EPS, annual-0.299-0.659-2.048-2.849-3.336-0.373-1.468-2.892
Period20182019202020212022202320242025
EPS, quarterly-0.662-0.652-0.673-0.436-0.753-1.265-1.702-0.972-1.18
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0.3792.3196.7879.3269.2249.76410.89718.618
Period20182019202020212022202320242025
Sales, quarterly2.0452.3362.9731.5733.84712.4750.85919.6353.004
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual37.51137.52737.56947.75469.76817.11417.11417.11417.106
Period20182019202020212022202320242025MRQ
Shares, quarterly109.266118.917.11417.10617.106146.77117.11417.10617.106
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY
Total Revenue3.0018.6210.909.76
Cost of Goods Sold Incl. D&A0.340.320.170.14
Gross Profit2.6618.3010.729.63
Selling, General and Administrative Excl. Other25.2867.9323.9416.01
Research and Development15.3444.2719.2012.65
Other Operating Expense0.000.000.000.00
Operating Income-22.62-49.63-13.22-6.39
Interest Expense0.000.000.000.00
Unusual Expense0.000.000.000.00
Net Income Before Taxes-20.19-49.64-13.22-6.38
Income Taxes0.00-0.1411.910.00
Consolidated Net Income-20.19-49.50-25.12-6.38
Net Income From Continuing Operations-20.19-49.50-25.12-6.38
Net Income-20.19-49.50-25.12-6.38
EPS (Recurring)-1.18-2.89-1.47-0.37
EPS (Basic, Before Extraordinaries)-1.18-2.89-1.47-0.37
EPS (Diluted)-1.18-2.89-1.47-0.37
EBITDA-22.27-49.31-13.05-6.25
Non-Operating Income (Expense)2.43-0.010.000.00
Other After Tax Adjustments0.000.000.000.00
Stock Option Compensation Expense0.896.072.512.51
Gross Margin-98.2798.4298.59
Operating Margin--266.58-121.30-65.40
Net Margin--265.88-230.54-65.39
Shares Outstanding17.1117.1117.1117.11
Market Capitalization183.33183.33--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q22025Q12024Q4
Total Revenue3.0019.640.863.851.572.97
Cost of Goods Sold Incl. D&A0.340.150.120.080.050.06
Gross Profit2.6619.480.743.771.522.92
Selling, General and Administrative Excl. Other25.2836.7629.8416.638.979.17
Research and Development15.3416.6614.2913.296.947.52
Other Operating Expense0.000.000.000.000.000.00
Operating Income-22.62-17.28-29.10-12.86-7.45-6.25
Interest Expense0.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.00
Net Income Before Taxes-20.19-16.63-29.10-12.88-7.45-6.25
Income Taxes0.000.000.030.000.005.26
Consolidated Net Income-20.19-16.63-29.14-12.88-7.45-11.51
Net Income From Continuing Operations-20.19-16.63-29.14-12.88-7.45-11.51
Net Income-20.19-16.63-29.14-12.88-7.45-11.51
EPS (Recurring)-1.18-0.97-1.70-0.75-0.44-0.67
EPS (Basic, Before Extraordinaries)-1.18-0.97-1.70-0.75-0.44-0.67
EPS (Diluted)-1.18-0.97-1.70-0.75-0.44-0.67
EBITDA-22.27-17.13-28.98-12.79-7.40-6.19
Non-Operating Income (Expense)2.430.650.00-0.010.000.00
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense0.8912.212.811.701.210.86
Gross Margin88.5899.2385.8097.9596.6398.05
Operating Margin-752.93-88.01-3,387.89-334.39-473.74-210.26
Net Margin-671.97-84.71-3,391.85-334.78-473.55-387.22
Shares Outstanding17.1117.1117.1117.1117.1117.11
Market Capitalization183.33233.49----

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY
Cash & Short Term Investments0.000.000.00
Short Term Receivables0.100.000.75
Inventories0.000.000.00
Other Current Assets1.530.480.10
Total Current Assets1.640.480.86
Net Property, Plant & Equipment5.516.709.44
Total Investments and Advances0.000.000.00
Intangible Assets0.000.000.00
Deferred Tax Assets0.591.552.22
Other Assets1.210.000.00
Total Assets8.958.7312.52
Short Term Debt Incl. Current Port. of LT Debt3.673.843.64
Accounts Payable4.400.530.50
Other Current Liabilities33.7322.4329.66
Total Current Liabilities41.8026.8033.80
Long Term Debt0.002.966.21
Provision for Risks Charges0.000.000.00
Deferred Tax Liabilities0.591.552.22
Other Liabilities29.2738.5340.90
Total Liabilities71.6669.8483.14
Non-Equity Reserves0.000.000.00
Preferred Stock - Carrying Value0.000.000.00
Common Equity-62.71-61.11-70.62
Total Shareholders Equity-62.71-61.11-70.62
Accumulated Minority Interest0.000.000.00
Total Equity-62.71-61.11-70.62
Total Liabilities & Stockholders Equity8.958.7312.52
Book Value Per Share-3.66-3.57-4.13
Tangible Book Value Per Share-3.66-3.57-4.13
Price to Book Ratio0.66--
Return on Assets-559.97-236.46-
Quick Ratio0.040.020.03
Current Ratio0.040.020.03

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY
Net Income-20.19-49.50-25.12-6.38
Depreciation0.340.320.170.14
Other Funds (Non Cash)1.408.2515.292.70
Funds from Operations-18.45-40.93-9.66-3.54
Extraordinary Item0.000.000.000.00
Changes in Working Capital14.52-0.20-12.8959.94
Cash from Operating Activities-3.93-41.13-22.5556.39
Capital Expenditures-0.04-1.45-0.27-0.32
Net Assets From Acquisitions0.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.00
Purchase or Sale of Investments-191.550.000.000.00
Purchase of Investments-191.550.000.000.00
Sale Or Maturity of Investments0.000.000.000.00
Other Uses0.000.000.000.00
Other Sources0.000.000.000.00
Cash from Investing Activities-191.59-1.45-0.27-0.32
Cash Dividends Paid0.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.00
Change in Capital Stock0.000.000.000.00
Repurchase of Common Pref Stock0.000.000.000.00
Sale of Common Pref Stock0.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.00
Change in Long Term Debt0.000.000.000.00
Issuance of Long Term Debt0.000.000.000.00
Reduction of Long Term Debt0.000.000.000.00
Net Financing Active Other Cash Flow0.0042.5722.82-56.07
Other Financing Activities Uses0.000.000.00-56.07
Cash from Financing Activities0.0042.5722.82-56.07
Net Change in Cash-195.51---
Free Cash Flow-3.96-42.57-22.8256.07
Deferred Taxes & Investment Tax Credit-0.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q22025Q12024Q4
Cash & Short Term Investments264.21267.850.00--0.00
Short Term Receivables0.0015.000.10--0.00
Inventories0.000.000.00--0.00
Other Current Assets10.842.581.53--0.48
Total Current Assets275.05285.561.64--0.48
Net Property, Plant & Equipment5.366.385.51--6.70
Total Investments and Advances0.110.410.00--0.00
Intangible Assets0.000.000.00--0.00
Deferred Tax Assets--0.59--1.55
Other Assets0.000.001.21--0.00
Total Assets280.51292.368.95--8.73
Short Term Debt Incl. Current Port. of LT Debt1.682.683.67--3.84
Accounts Payable3.510.814.40--0.53
Other Current Liabilities26.3118.4233.73--22.43
Total Current Liabilities31.5121.9141.80--26.80
Long Term Debt0.000.000.00--2.96
Provision for Risks Charges0.000.000.00--0.00
Deferred Tax Liabilities--0.59--1.55
Other Liabilities34.4336.3529.27--38.53
Total Liabilities65.9458.2671.66--69.84
Non-Equity Reserves0.000.000.00--0.00
Preferred Stock - Carrying Value0.000.000.00--0.00
Common Equity214.58234.10-62.71---61.11
Total Shareholders Equity214.58234.10-62.71---61.11
Accumulated Minority Interest0.000.000.00--0.00
Total Equity214.58234.10-62.71---61.11
Total Liabilities & Stockholders Equity280.51292.368.95--8.73
Book Value Per Share12.5413.69-3.66---3.57
Tangible Book Value Per Share12.5413.69-3.66---3.57
Price to Book Ratio0.661.00----
Return on Invested Capital-9.41-7.10----
Quick Ratio8.7313.040.04--0.02
Current Ratio8.7313.040.04--0.02

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q22025Q12024Q4
Net Income-20.19-16.63--12.88-7.45-
Depreciation0.340.15-0.080.05-
Other Funds (Non Cash)1.4013.05-1.781.27-
Funds from Operations-18.45-3.43--11.02-6.13-
Extraordinary Item0.000.00-0.000.00-
Changes in Working Capital14.52-27.71--0.89-4.97-
Cash from Operating Activities-3.93-31.14--11.91-11.10-
Capital Expenditures-0.04-2.10--0.270.00-
Net Assets From Acquisitions0.000.00-0.000.00-
Sale of Fixed Assets and Businesses0.000.00-0.000.00-
Purchase or Sale of Investments-191.550.00-0.000.00-
Purchase of Investments-191.550.00-0.000.00-
Sale Or Maturity of Investments0.000.00-0.000.00-
Other Uses0.000.00-0.000.00-
Other Sources0.000.00-0.000.00-
Cash from Investing Activities-191.59-2.10--0.270.00-
Cash Dividends Paid0.000.00-0.000.00-
Preferred Dividends (Cash Flow)0.000.00-0.000.00-
Change in Capital Stock0.000.00-0.000.00-
Repurchase of Common Pref Stock0.000.00-0.000.00-
Sale of Common Pref Stock0.000.00-0.000.00-
Proceedsfrom Stock Options0.000.00-0.000.00-
Issuance or Reduction of Debt, Net0.000.00-0.000.00-
Change in Long Term Debt0.000.00-0.000.00-
Issuance of Long Term Debt0.000.00-0.000.00-
Reduction of Long Term Debt0.000.00-0.000.00-
Net Financing Active Other Cash Flow0.00301.50-12.1711.10-
Other Financing Activities Uses0.000.00-0.000.00-
Cash from Financing Activities0.00301.50-12.1711.10-
Net Change in Cash-195.51268.26-0.000.00-
Free Cash Flow-3.96-33.24--12.17-11.10-

Revenue breakdown

Pharmaceutical Preparations2024: 10.90M 2025: 18.76M
United States2024: 10.90M 2025: 18.76M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3017.34%3.7M21.6M276.69K
2026-10-1517.24%3.7M21.6M257.55K
2026-09-3020.46%3.4M16.6M242.30K
2026-09-1519.88%3.4M17.1M220.60K
2026-08-3119.61%3.4M17.1M182.76K
2026-08-1420.37%3.5M17.1M193.28K
2026-07-3120.59%3.5M17.1M200.97K
2026-07-1521.04%3.6M17.1M251.36K
2026-06-3021.42%3.7M17.1M311.16K
2026-06-1521.18%3.6M17.1M371.58K
2026-05-2921.40%3.7M17.1M572.65K
2026-05-1521.86%3.7M17.1M761.86K
2026-04-3020.02%3.4M17.1M906.96K
2026-04-15-3.0M-1.08M
2026-03-31-1.9M-1.32M
2026-03-13-1.2M-2.03M
2026-02-27-0.4M-7.96M
2026-02-13-101.6M-22.07M
2026-01-306.30%87.5M1388.4M27.13M
2026-01-156.09%84.1M1381.1M47.67M

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-028-KCurrent report2026-11-02SEC
2026-10-278-KCurrent report2026-10-27SEC
2026-10-098-K/A2026-10-07SEC
2026-10-088-KCurrent report2026-10-07SEC
2026-09-224Statement of changes in beneficial ownership of securities2026-09-18SEC
2026-09-224Statement of changes in beneficial ownership of securities2026-09-18SEC
2026-09-224Statement of changes in beneficial ownership of securities2026-09-18SEC
2026-09-224Statement of changes in beneficial ownership of securities2026-09-18SEC
2026-09-224Statement of changes in beneficial ownership of securities2026-09-18SEC
2026-09-224Statement of changes in beneficial ownership of securities2026-09-18SEC
2026-09-224Statement of changes in beneficial ownership of securities2026-09-18SEC
2026-09-224Statement of changes in beneficial ownership of securities2026-09-18SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13GSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-07-27SCHEDULE 13G/ASEC
2026-07-148-KCurrent report2026-07-14SEC
2026-05-15SCHEDULE 13GSEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-148-KCurrent report2026-05-14SEC
2026-04-27SCHEDULE 13GSEC
2026-04-224Statement of changes in beneficial ownership of securities2026-04-20SEC
2026-04-224Statement of changes in beneficial ownership of securities2026-04-20SEC
2026-04-224Statement of changes in beneficial ownership of securities2026-04-20SEC
2026-04-224Statement of changes in beneficial ownership of securities2026-04-20SEC
2026-04-224Statement of changes in beneficial ownership of securities2026-04-20SEC
2026-04-17S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-04-08SCHEDULE 13GSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-01004.23M13
2025-120000
2025-110000

Institutional holders

Manager% owned
Sessa Capital IM, L.P.8.77%
PRICE T ROWE ASSOCIATES INC /MD/8.61%
BlackRock, Inc.8.46%
CRCM LP7.50%
Arbiter Partners Capital Management LLC4.58%
VANGUARD CAPITAL MANAGEMENT LLC4.27%
TIG Advisors, LLC3.28%
CANTOR FITZGERALD, L. P.3.00%
GEODE CAPITAL MANAGEMENT, LLC2.22%
TWO SIGMA INVESTMENTS, LP2.02%

Funds

Fund% owned
T. Rowe Price Health Sciences Fund, Inc.3.31%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.03%
T. Rowe Price New Horizons Fund, Inc.2.59%
iShares Russell 2000 ETF2.21%
VANGUARD EXTENDED MARKET INDEX FUND1.10%
BlackRock Event Driven Equity Fund1.03%
Fidelity Small Cap Index Fund0.90%
Nexpoint Merger Arbitrage Fund0.79%
Janus Henderson Small Cap Growth Alpha ETF0.69%
iShares Russell 2000 Growth ETF0.52%

OakChart. RNA. Cached 15 minutes.